Candriam S.C.A. Supernus Pharmaceuticals, Inc. Transaction History

Candriam S.C.A.

$17.1 Billion
Q3 2024

A detailed history of Candriam S.C.A. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 141,889 shares of SUPN stock, worth $5.13 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

141,889

Previous 141,889 -0.0%

Holding current value

$5.13 Million

Previous $3.8 Million 16.57%

% of portfolio

0.03%

Previous 0.02%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	BUY	$25.99 - $33.85 $3.69 Million - $4.8 Million	141,889 New	141,889 $3.8 Million
Q4 2020 Jan 22, 2021	SELL	$17.7 - $25.81 $354,000 - $516,200	-20,000 Closed	0 $0
Q3 2020 Oct 19, 2020	SELL	$20.2 - $25.05 $282,800 - $350,700	-14,000 Reduced 41.18%	20,000 $417,000
Q2 2020 Jul 23, 2020	SELL	$17.09 - $24.89 $2.72 Million - $3.96 Million	-159,000 Reduced 82.38%	34,000 $808,000
Q4 2019 Jan 21, 2020	SELL	$19.93 - $29.13 $1.97 Million - $2.88 Million	-99,000 Reduced 33.9%	193,000 $5,000
Q3 2019 Oct 21, 2019	BUY	$25.47 - $33.37 $178,290 - $233,589	7,000 Added 2.46%	292,000 $8,000
Q2 2019 Aug 01, 2019	BUY	$29.96 - $38.87 $2.25 Million - $2.92 Million	75,000 Added 35.71%	285,000 $9.39 Million
Q1 2019 May 02, 2019	BUY	$32.77 - $41.99 $2.46 Million - $3.15 Million	75,000 Added 55.56%	210,000 $7.36 Million
Q4 2018 Feb 14, 2019	BUY	$30.84 - $49.51 $4.16 Million - $6.68 Million	135,000 New	135,000 $4.49 Million
Q4 2017 Feb 07, 2018	SELL	$36.4 - $42.6 $3.24 Million - $3.79 Million	-89,000 Closed	0 $0
Q3 2017 Nov 03, 2017	BUY	$36.75 - $49.65 $3.27 Million - $4.42 Million	89,000	89,000 $3.56 Million

Others Institutions Holding SUPN

# of Institutions

281

Shares Held

60.6M

Call Options Held

27.7K

Put Options Held

11.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.93B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account